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Abstract
Chitosan oligosaccharides (COS) have been introduced as marine-derived biomaterials with potential health benefits and
good water solubility properties. This study presents an overview of the promising nanomaterial platform for biomedical
and pharmaceutical applications of COS. The health benefits of COS, primarily their antioxidant and protective effects,
anti-inflammatory activity, antidiabetic properties, and cholesterol-lowering effects are discussed. Furthermore, the promising recent articles on specific topics such as drug delivery systems and nanobiomaterials, are highlighted.
Keywords: antioxidants, biomaterials, chitosan oligosaccharides, drug delivery systems, nanoparticles

Several review articles have focused on COS-based biomaterials or their specific applications [3, 8, 9]. Park and
Kim [8] reviewed the biological activities of chitin and
COS and their applications as drug delivery systems
(DDS). Satitsri and Muanprasat [9] summarized the potential of COS as biomaterials applicable for treating a
variety of diseases. Kumar and Kumar [3] studied the biomedical applications of COS, including drug and gene
delivery and tissue engineering. The limitations of these
studies include the absence of COS-based nanomaterial
and the COS applications in the biomedical and pharmaceutical fields are limited to drug delivery and tissue engineering. A review focusing on COS-based nanomaterials is highly needed but is still lacking. Thus, in this study,
recent articles on COS-based nanomaterials, biological
properties, and their applications in biomedicine and
pharmaceutics are highlighted.

Introduction
Nanomaterials have emerged as a platform for improving
the functionalities of various compounds in different fields.
Applying nanomaterials has several advantages, such as
enhancing activity and properties, easy modification, and
targeted activity [1]. Nanomaterials have been synthesized
from a wide range of materials, such as polysaccharides,
proteins, inorganic materials, metallic compounds, and
others. Among these, polysaccharides are one of the
promising materials due to their proven safety, costeffectiveness, as well as biological and therapeutic
activities [2]. Chitin and chitosan, as well as their
oligomers, are being considered for applications due to
their bioactive properties, non-toxicity, biocompatibility,
and biodegradability [3, 4]. These marine-derived amino
polysaccharides provide important structural and
functional properties for various food, pharmaceutical,
and biomedical applications. However, the use of chitin
and chitosan is limited due to their high viscosity and low
solubility at neutral pH, [5]. Chitosan oligosaccharides
(COS) are the hydrolyzed forms of CS that have been
introduced as potential biomaterials because they exhibit
a wide range of biological activities and may have health
benefits [6]. We hypothesized that COS have better
capability than CS in promoting health due to their high
solubility and remarkable biological activities. Several
studies have shown that COS have anti-allergy, antiarthritis, immuno-activating, neuroprotective, and other
potential health effects, such as antioxidant, anticholesterol,
antidiabetic, and antiinflammatory effects [7]. Therefore,
COS have emerged as a biomaterial platform to
synthesize nanomaterials.

Structure and Chemistry of COS
COS are a degraded form of CS, an amino polysaccharide
that is commonly extracted from crustacean shells. COS
consist of N-acetyl-D-glucosamine (GlcNAc) and
glucosamine (Glc) units linked with -1, 4 glycosidic
bonds (Figure 1). Although their chemical structure is
similar to CS, they have a lower molecular weight (MW)
and degree of polymerization (DP) than CS, making them
soluble in water and at neutral pH. Generally, CS with an
MW and DP below 10 kDa and 20, respectively is
considered as COS [6, 7]. However, those with an MW
of 24 kDa and DP of 62 are still considered COS due to
their water solubility [10]. Lower DP (DP of 2–12) COS
are of great interest because of their potential health
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benefits [11–13]. COS are positively charged from the
free amino groups in the Glc units, which allows them to
bind with negatively charged molecules and promote
biological applications [14]. Moreover, COS have been
produced by hydrolyzing CS using physical (microwave
and ultrasonic treatments), biological (chitosanases and
celluloses), and chemical (acid hydrolysis and oxidative
degradation) methods [15] (Figure 2). COS with a
defined MW, DP, degree of acetylation (DA), and
acetylation pattern (AP), are desired because of their
biological and physiological activities [16].

Biological Properties of COS
In this section, this study briefly highlights some of the
important biological properties of COS that draw the
attention of experts in the synthesis of nanomaterials.
Refs [4, 7, 14, 18] are recommended for a more
comprehensive review of the biological properties of
COS. Unfortunately, the validation methods for the
biological assays (antioxidant, antiinflamatory activity as
well as antidiabetic, anticholesterol, and antibacterial
effects) and authentication of the microorganisms used
were not reported in all of the publications cited below.
Thus, the reliability of the reported data may not be
confirmed.

Figure 1. Structure of COS. Reproduced from [17] Under
the Terms of the Creative Commons Attribution
4.0 International License (http://creativecommon
s.org/licenses/by/4.0/).

Figure 2. COS Production Method
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Antioxidant and protective effects. Several in vitro
studies have shown that COS possess strong antioxidant
properties. Their free radical scavenging activity has been
studied using the electron spin resonance method, where
COS with an MW of 1–10 kDa show prominent
scavenging activity on hydroxyl radicals, superoxide
radicals, alkyl radicals, and 2,2-diphenyl-1-picrylhydrazyl
radicals [19]. These are common free radicals with
stronger scavenging activity on hydroxyl and superoxide
radicals. The antioxidant activity of COS is associated with
DP and depends on MW, DA, and the free radicals tested.
In general, the higher DA of COS, the higher the
antioxidant activity of COS, while medium MW COS
(1–5 kDa) exhibits the highest antioxidant activity [11,
19].
The first study on the antioxidant and protective effects
of COS in the cellular oxidizing system was reported by
Kim et al. [20]. They discovered that low molecular COS
(<1 kDa) suppress radicals and protects deoxyribonucleic
acid (DNA) against oxidative damage in the B16F1
murine melanoma cell line. A correlation was detected
between the presence of COS and the induction of the
naturally occurring intracellular antioxidant glutathione
(GSH). Moreover, several studies have been carried out
using biological systems. These included a test on two
biological oxidizable substrates, such as erythrocytes and
bacteriophages, where two COS mixtures (<3 and <5
kDa), and low MW COS (<1 kDa) protected DNA
against hemolytic damage [21]. It has also been reported
that COS can protect Chang liver cells from oxidative
damage induced by tert-butylhydroperoxide by inhibiting
reactive oxidative species (ROS) production and lipid
peroxidation [22].
A previous study reported that COS are potential
neuroprotective agents for treating neurodegenerative
diseases because of their ability to prevent glucose
deprivation-induced cell apoptosis [23]. Similarly, COS
are a potential biomaterial in the treatment of
cardiovascular disease [24, 25]. COS protect human
umbilical vein endothelial cells (HUVECs), which are
commonly used to study the pathogenic mechanisms of
cardiovascular diseases [24]. COS increase viability, and
proliferative activity, and recover nuclear chromatin
damage in HUVECs. COS (100–200 µg/ml) protected
endothelial cells from oxidative damage similar to
vitamin C (250 µg/mL) [24].
Several attempts have been made to improve the cellular
antioxidant activity of COS by combining COS with
certain antioxidants, such as phenolic compounds [26].
Covalently linked COS and gallic acid improve
intracellular ROS scavenging activity and oxidative
inhibition of DNA, proteins, and lipids in mouse
macrophages (RAW 264.7 cells) and human
chondrosarcoma (SW 1353 cells).
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In animal studies, COS protect pancreatic islet cells from
streptozotocin (STZ)-induced diabetes in rats. Moreover,
COS ranging from 250 to 1,500 mg/kg body weight (b.w)
in a dose-dependent manner enhanced the total
antioxidant capacity, and superoxide dismutase activity,
and significantly decreased serum malondialdehyde
(MDA) levels. Based on morphological observations,
COS protected the pancreas against STZ, where the
greatest protective effect occurred with the medium
dosage (500 mg/kg b.w of COS) [27]. Another study
examined the protective effect of COS against sepsis, a
systemic inflammatory response induced by infection. As
a result, COS (100 mg/kg b.w) decreased MDA levels in
the liver, lungs, and kidneys of mice, and increased GSH,
and catalase activities. Furthermore, COS treatment
improved the survival rate of mice after injecting a
proinflammatory agent [28], and 500 mg/kg b.w COS
restored serological parameters, including blood urea
nitrogen, creatinine, and histology in rats after a paraquat
injection [29]. COS have protective effects on intestinal
integrity and are a promising novel anti-aging compound
in the mouse model [30–32].
Despite the encouraging results of in vitro and animal
studies, the antioxidant activities of COS have rarely
been reported in clinical trials. One study reported the
antioxidant activity of COS with an MW of 20 kDa and
a degree of deacetylation (DD) of 95% [33]. In that study,
10 healthy subjects aged 23–35 years were given a single
daily dose of 540 mg COS. After 4 weeks of treatment,
human serum albumin (HSA) and total plasma
antioxidant capacity were measured in a blood sample.
HSA was used as the marker of oxidative stress in
systemic circulation. The study showed that COS
significantly lowered the oxidized albumin ratio by
18.6% (p < 0.05) and increased total antioxidant capacity
by 44.2% (p < 0.05) after 4 weeks of treatment. They also
examined the antioxidant properties of high molecular
weight chitosan (HMWC) with an MW of 100 kDa [34]
using a similar method. The results showed that HMWC
supplementation significantly lower the oxidized
albumin ratio by 12.5% (p < 0.05) and 11.8% (p < 0.05)
after 4 and 8 weeks of treatment, respectively. Similarly,
HMWC increased total plasma antioxidant capacity by
32.6% (p < 0.05) and 24.8% (p < 0.05) after 4 and 8
weeks of treatment, respectively. A clinical trial
discovered that COS have stronger antioxidant activity
than CS possibly due to the weak intra and intermolecular hydrogen bonds.
Anti-inflammatory activity. Pro-inflammatory cytokines,
such as interleukin (IL)-1 and tumor necrosis factor-alpha
(TNF-α), cause inflammation. Therefore, several studies
have focused on decreasing or blocking the release of
pro-inflammatory cytokines using COS to reduce their
biological activities [35] and exert antiinflammatory
properties.
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Studies on the antiinflammatory effects of COS have
been carried out using various methods, and have been
primarily based on inhibiting TNF-α, IL-1, and IL-6. In
an in vitro study, 5 mg/mL COS with MW of 1–3 kDa
significantly decreased the expression of inducible nitric
oxide synthase (iNOS), which was associated with the
inflammatory response [36]. It was reported that COS
(0.05%–0.1%) recovered the levels of IL-6, and TNF-α
proinflammatory cytokines in RAW 264.7 macrophage
cells after injection of lipopolysaccharides (LPS), which
increased the levels of TNF-α and IL-6. They also
suggested that the antiinflammatory activity of COS was
associated with the ability to affect TNF-α secretion [37].
An in-depth study on the molecular mechanisms of the
anti-inflammatory activity of COS on LPS-induced
RAW 264.7 macrophages was reported [38]. The
inhibitory effects of a CS oligomer mixture (DD > 95%)
on the overexpression of IL-6 and TNF-α were observed
at the transcriptional and translational levels. COS (50–
200 µg/mL) significantly suppressed the overexpression
of IL-6 and TNF-α according to a reverse transcriptionpolymerase chain reaction analysis used to monitor
mRNA transcription. A similar result was observed at the
translational level, in which the production of IL-6 and
TNF-α decreased significantly. COS have also shown
suppressive effects on the phosphorylation of p38
mitogen-activated protein kinases (MAPKs), extracellular
regulated kinases (ERK) 1/2, and c-Jun N-terminal
kinases. These are the corresponding protein kinases for
inflammatory signaling, inflammation-activating enzyme
phosphatidylinositol 3-kinase, and protein kinase B
(Akt), respectively. Furthermore, COS also inhibit the
activation of nuclear factor-kB (NF-kB) and activator
protein-1, which play an important role in inflammation
[38].
Other studies have been carried out using HUVECs as a
common tool to investigate vascular inflammation. The
antiinflammatory activity of COS on LPS-induced
HUVECs was slightly similar to LPS-induced RAW
264.7 cells. A COS (200 µg/ml) treatment suppressed
transcription and translation of IL-6 by 35.5% and
60.9%, respectively compared with the LPS treatment.
Furthermore, COS (200 µg/mL) inhibited the NF-kB
protein by blocking NF-kB translocation from the
cytoplasm to the nucleus and recovered the IkBα protein,
which is an NF-kB inhibitory protein. The inhibitory
effects of COS on p38 MAPK and ERK1/2 expression
have been observed in LPS-induced HUVECs [39].
Moreover, COS inhibit the production and expression of
adhesion molecules, such as vascular cell adhesion
molecule 1 (VCAM-1), which promote vascular
inflammation [40]. The antiinflammatory activity of
COS on human THP-1 monocytes was also observed by
reducing proinflammatory cytokines in a dose-dependent
manner [41].
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The first in vivo study of the anti-inflammatory activity
of COS was reported by Fernandes et al. using a
carrageenan-induced paw edema model, with two kinds
of COS (1.2 kDa and 5.3 kDa) and DDs of 80%–85%
[42]. They compared the activity with that of
indomethacin (INN) as a positive control. Both INN and
COS were injected into Balb/c mice 1 hour before the
carrageenan injection, and the levels of paw edema were
measured after 3 and 6 hours. Both COS at all
concentrations (10, 30, 100, and 500 mg/kg b.w)
decreased paw edema compared with the negative
control, and the best activity was obtained at a dose of
500 mg/kg b.w [42]. The antiinflammatory activity of
COS was compared with that of INN for up to 24 hours,
however, the activity decreased for the next 24 hours.
They concluded that the effects of COS depended on the
MW, in which lower MW COS had better activity than
higher MW COS. The proposed COS antiinflammatory
mechanism occurs by inhibiting cyclooxygenase (COX)
products, which are mediators of inflammation, by
downregulating proinflammatory cytokines, such as
TNF-α, IL-6, iNOS, and COX-2. The COS used in that
study were considered to be safe as they did not damage
the internal organs of the mice after treatment [42]. More
recent in vivo studies have shown that COS are a potential
therapeutic biomaterial to treat inflammation [30, 43–45].
Antidiabetic effect. Damage to the pancreatic β-cells has
been reported to cause diabetic complications. Pancreatic
β-cells must be protected because of their susceptibility
to oxidative damage due to the low expression of
antioxidant enzymes. An in vitro study showed that COS
protected pancreatic β-cells from oxidative damage [27,
46] by preventing apoptosis in pancreatic islet cells (NIT1). It was discovered that COS significantly improved the
capability of antioxidant enzymes and increased the
protective effect on pancreatic islet cells from oxidative
damage [27]. COS can also amplify the INS-1 cells,
increase insulin secretion by promoting glucose
transporter (GLUT2) gene expression, and protect
pancreatic β-cells from apoptosis induced by STZ [47].
Animal and cell studies have been carried out on the
antidiabetic effect of COS. The first in vivo study on the
antidiabetic effect of COS was conducted using STZinduced diabetic rats [48]. The results showed that COS,
with an MW of <1.5 kDa, successfully increased glucose
tolerance and insulin secretion after 4 weeks of treatment.
Furthermore, the COS lowered the glucose levels of
diabetic rats and significantly decreased fed-triglyceride
(TG) levels by 49%, indicating the ability to lower TG in
diabetic rats. However, no significant change in glucose
tolerance was observed with water containing 0.1%
ascorbic acid [48].
Similar results were obtained in more recent studies by
several authors [27, 47, 49–51]. COS with an average
MW of 1.2 kDa were administered to STZ-induced
Makara J. Sci.
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diabetic rats at different concentrations of 250, 500, and
1,500 mg/kg b.w per day. After 60 days of treatment, 2hour plasma, urine, and oral glucose tolerance tests were
conducted. The best result was shown in the 500 mg/kg
b.w concentration group, which decreased urine and
plasma glucose levels to 16.14 mmol/L (p < 0.01) and
significantly improved glucose tolerance with a blood
glucose area under the curve of 68.7% [27]. Another
study reported that COS improve oral glucose tolerance
and decreases fasting blood glucose and insulin. In this
study, a significant increase in liver glycogen and
glucokinase was observed in the rats after the COS
treatment. COS improved the pancreas-to-body weight
ratio and minimized damage to the pancreas of diabetic
rats [47]. A study on the antidiabetic effect of COS using
lower dosages (5 mg and 10 mg/kg b.w per day) in
diabetes alloxan-induced mice revealed promising
antidiabetic activities at lower concentrations [51].
The first human clinical trials on the antidiabetic effect
of COS were reported by Kim et al. [52]. As a result,
Koreans with normal blood glucose levels and
supplemented with 500 mg of COS had significantly
lower postprandial blood glucose levels. This occurred
30 min after the meal by stimulating the action of insulin
and inhibiting carbohydrate-hydrolyzing enzymes that
decrease the release of glucose from the meal [52, 53].
COS supplementation also significantly decreases serum
glucose levels after 12 weeks of supplementation [54].
COS effectively lowered the postprandial blood glucose
levels of subjects with impaired glucose tolerance,
fasting, and healthy glucose status [55].
Although the COS antidiabetic mechanisms have not
been well-established, several mechanisms have been
suggested. It has been proposed that COS protect
pancreatic β-cells from oxidative damage due to their
antioxidant activity. It has been suggested that pancreatic
β-cells are strongly correlated with the incidence of
diabetes [46]. One report showed that COS enhance the
performance of pancreatic β-cells by promoting
proliferation and the recovery of damage [27]. COS also
maintain glucose homeostasis by lowering excess plasma
glucose under diabetic conditions. This is due to their
endocrine property of regulating the secretion of insulin
and promoting the normal metabolism of plasma glucose.
In addition, COS stimulate glucose to produce liver
glycogen [47]. COS enhance insulin sensitivity by
reducing the levels of tumor necrosis factor  (TNF-α)
and interleukin 6 (IL-6), and increasing adiponectin
concurrently [50]. A recent study showed that COS
inhibit digestion, transport, and uptake of glucose by
inhibiting intestinal -glucosidase and the glucose
transporters, sodium-dependent glucose transporter 1
(SGLT1) and GLUT2, and enhances adipocyte
differentiation as well as peroxisome proliferatoractivated receptor  (PPAR) expression [49].
December 2022  Vol. 26  No. 4
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Anticholesterol effect. High blood cholesterol is a major
risk factor for cardiovascular disease [56]. Therefore, it
is important to maintain blood cholesterol at a normal
level. One way to restore the blood cholesterol level is to
use a cholesterol-lowering drug; however, adverse
effects can make these drugs unfavorable [57]. CS has
been promoted as a natural safe material to lower blood
cholesterol [58]. COS have been increasingly studied due
to their better solubility and biocompatibility compared
with CS. COS have shown blood cholesterol-lowering
activity in an animal model and a clinical trial.
A study using hyperlipidemic rats revealed that the
supplementation with COS (250 and 750 mg/kg b.w) for
3 weeks significantly decreases rat plasma triglyceride
(TG) and increases plasma high-density lipoprotein
(HDL)-cholesterol by 29%–31% and 8%–11%,
respectively. Furthermore, the lipid fractions were
affected by COS. It was discovered that COS decrease
plasma very low-density lipoprotein and low-density
lipoprotein (LDL) fractions and increases plasma HDL
fractions using protein liquid chromatography. COS also
lower the portion of the main apolipoprotein in LDL,
apoB48, and B100. One experiment showed that COS do
not affect plasma apoA-I, which is a major HDL
apolipoprotein, indicating a major role in stimulating
maturation or interfering with HDL catabolism. More
importantly, COS significantly enhance the activity of
lecithin cholesterol acyl transferase, an enzyme
responsible for regulating the HDL cholesterol level. It
has been suggested that COS affect lipid regulation,
lipoprotein profiles, and regulatory enzymes. However,
COS do not significantly reduce LDL-cholesterol levels
[57].
In contrast, one study reported that supplementing mice
with COS for 4 weeks significantly decreased total and
LDL-cholesterol levels but did not affect the HDL
cholesterol level [59]. They also investigated the effect
of COS on reverse cholesterol transport (RCT), which
promotes the secretion of cholesterol into bile acids,
leading to increased cholesterol excretion through the
feces. An isotope-labeled cholesterol-tracing assay was
used to evaluate RCT in mice, and several genes and
proteins associated with cholesterol transport such as
scavenging receptor class type I (SR-BI), cholesterol 7hydroxylase
(CYP7A1),
ATP-binding
cassette
transporters (ABCA1/ABCG1), and LDL-receptor
(LDL-R) were observed by western blot. This treatment
increased the expression of SR-BI, which regulates the
transport of cholesterol from the plasma to the liver
without affecting the expression of ABCA1/ABCG1.
These are the main cholesterol transporters, indicating
that COS are partially related to enhanced hepatic SR-BI
expression. Moreover, the accumulation of 3Hcholesterol in the bile and feces of mice indicates that
COS improve the expression of CYP7A1, which is an
important gene in bile acid synthesis. The LDLMakara J. Sci.

cholesterol-lowering effect of COS is due to their ability
to increase the expression of the LDL-receptor. COS are
a safe lipid-regulating treatment because they do not
affect the metabolism of other lipids or morphology in
mice [59]. In more recent studies, COS lowered
cholesterol levels by enhancing the expression of hepatic
LDL-R and SR-BI, CYP7A1, liver X receptor alpha, and
PPAR- and facilitated the conversion of cholesterol to
bile acids [60,61]. However, the cholesterol-lowering
effect of COS is slightly lower than that of CS [62]. In
addition, COS have been proposed to be nutraceuticals
for treating obesity due to their ability to control weight
gain, improve dyslipidemia, and inhibit hepatic lipid
accumulation [63–65].
Only one human study has reported on the anticholesterol
activity of COS. Nineteen healthy men (11 smokers and
8 nonsmokers) received 500 mg COS of MW < 1 kDa
and a DD of 90% orally twice daily. It was concluded that
1 g per day of COS for 6 weeks significantly lowered the
total cholesterol and LDL-cholesterol levels of the
participants compared with those at baseline. This
finding shows that COS play an important role in
changing the cholesterol metabolic pathway due to their
ability to bind lipids and bile acids [66, 67].
Antibacterial activity. The antibacterial activity of COS
has been reported by several studies, in which the growth
of gram-positive bacteria, such as Staphylococcus
aureus, with a low minimum inhibitory concentration of
1.13 µg/mL, was inhibited [68]. COS with an MW < 50
kDa, DD of 88.76%, and a concentration of 0.25%
effectively inhibited the growth of E. coli, which is a
gram-negative bacterium. The inhibitory effect of COS
against E. coli increases with decreasing MW and vice
versa [69]. In a recent study, the antibacterial activity of
COS was tested against four gram-positive bacteria, such
as S. aureus ATCC 43300 and 25923, Bacillus subtilis,
B. cereus, and eight gram-negative bacteria, including E.
coli, Pseudomonas aeruginosa, Salmonella typhimurium,
Vibrio cholerae, Shigella disenteriae, Enterobacter
agglomerans,
Prevotella
melaninogenica,
and
Bacteroides fragilis. The results showed that COS were
effective in inhibiting the growth of all of the bacteria
tested. Additionally, the antibacterial activity of COS
was better than that of chitin and CS. COS penetrated the
bacteria cell wall, whereas chitin and CS only flocculated
the bacteria. This observation shows that COS can act as
a bactericidal agent, while chitin and CS merely act as
bacteriostatic agents [70]. However, a different result has
been reported, in which CS had better antimicrobial
activity than COS [71]. Moreover, the possible
mechanisms for the antibacterial activity of COS include
flocculation of bacteria, preventing nutrients from
entering the cell by forming a polymer membrane,
electrostatic interaction with the components of the cell
surface of the bacteria, and penetration into the cell wall
of the bacteria [69, 70, 72].
December 2022  Vol. 26  No. 4
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Safety of COS
Human lymphocytes are an appropriate model for
evaluating the biocompatibility and safety of a
compound, as they play an important role in the immune
system. Thus, the toxicity of COS was evaluated on
human lymphocytes [73]. It was concluded that a
concentration > 0.07 mg/ml was cytotoxic in a dosedependent manner, but no genotoxic activity was
observed. Another study demonstrated that no subacute
toxicity was observed in rats given 2,000 mg/kg b.w./day,
showing that COS supplementation was safe [74]. Qin et
al. (2006) indicated that short-term (30 days)
supplementation of rats with COS is safe because no
adverse effects were observed after a 3 g/kg b.w/day
treatment [75]. Similarly, COS do not affect DNA,
plasma membrane integrity, motility, and morphology of
sperm cells, suggesting the absence of acute toxicity [76].
COS supplementation was safe in a clinical trial [54].
Moreover, COS-based nanoparticles (NPs)(500 g/mL)
have relatively low toxicity in vitro [77]. However, more
studies are needed to ensure the safety of COS-based
nanomaterials in clinical studies because nanosized
materials can be toxic to the body.

Synthesis of COS-based Nanomaterials
COS conjugates and micelles. COS-based conjugates
are formed by linking COS with another compound
through physical, chemical, or enzymatic processes [78]
to endow COS with intended characteristics and improve
the biological activities of COS. COS have been
conjugated with proteins, inorganic compounds,
polymers, and small molecules [78–81] using chemical
methods. An amine-reactive crosslinker is widely used
because the conjugation reaction is straightforward and
cost-effective. This includes N-hydroxysuccinimide
esters (NHS) and carbodiimide (EDC) [82], which are
used to directly conjugate carboxylates to primary
amines. EDC is also used with NHS to improve the
conjugation reaction and create a more stable
intermediate [83]. In rare cases, COS-based conjugates
can be formed by simple mixing with the intended
compounds followed by drying [81]. COS-based
micelles are among the most popular nanomaterials used
for several applications, such as DDSs. Micelles are selfassembled nanomaterials formed from amphiphilic
molecules. The size of the micelles is 5–100 nm [84].
Furthermore, COS-based micelles are formed by
covalently joining fatty acids as hydrophobic compounds
to hydrophilic COS [85, 86] using EDC and NHS as
crosslinkers.
COS Nanoparticles. COS NPs are among the most
popular nanomaterials and have been fabricated by
several bottom-up methods, such as emulsion,
desolvation, and ionic crosslinking/electrostatic
interactions/polyelectrolyte complexation [1]. In the
Makara J. Sci.
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emulsion method, the W/O surfactant acts as a template
to fabricate the COS NPs. In addition, crosslinking agents
are usually used to strengthen the integrity of the NPs.
However, the drawbacks of this method are the additional
washing of the surfactant and the use of toxic
crosslinkers. The most popular method for making COS
NPs is ionic crosslinking, in which the COS and anionic
small molecule crosslinkers, such as tripolyphosphates,
are mixed in an aqueous solution [5]. The mixing allows
the electrostatic interactions between them, and COS are
organized into spherical NPs. This method is popular due
to its mild and easy reactions and it is free of toxicity.
COS NPs have also been fabricated by polyelectrolyte
complexation [87] using small molecules, proteins, and
anionic polysaccharides. More stable COS NPs with
additional properties have been synthesized through
hydrophobic and electrostatic interactions. However, the
drawback of this method is the relatively large size of
NPs (> 150 nm) and the yield significantly depends on
the magnitude of the interactions between the mixed
compounds [88]. The desolvation method is also used to
make COS NPs. This method is a simple coacervation or
phase separation, in which macromolecular aggregation
is induced by solvated molecules [1]. Similar to the
emulsion method, a surfactant is frequently used to
stabilize the NPs suspension.
COS as supporting materials. COS are widely used as
supporting material to fabricate nanomaterials due to
their inherent biological properties. Fabrication of
hydrophobic nanomaterials, such as carbon- and
metallic-based nanomaterials, requires the use of a
hydrophilic compound for solubilization during the
preparation of nanomaterials [17, 89–91]. COS can
support such nanomaterials based on the formation of
NPs and improved bioactivity. The benefits of COS
properties, such as high water-solubility, low viscosity,
antimicrobial, and anticancer, have attracted their use as
supporting nanomaterials in several studies [14]. In
addition, they are cost effective, abundant, and
biocompatible and can be used in the biomedical and
pharmaceutical fields. The general synthetic method for
COS as supporting nanomaterials is by physical mixing
or blending with other components to form COS-based
nanocomposites with unique properties. A COS solution
and various components are uniformly blended, followed
by the sol gel transition and formation of the
nanocomposite [66].

Applications of COS-based Nanomaterials
Drug delivery systems. A DDS is an excellent tool for
delivering bioactive compounds, such as drugs, to the
desired target. A DDS also aids in the long-term stability
of the bioactive compound, which has added to popularity
during the last two decades. COS-based nanomaterials
have been used as delivery systems for a wide variety of
compounds, such as small molecule drugs, proteins,
December 2022  Vol. 26  No. 4

244 Razi, et al.

nucleic acids, and antioxidants [92–95]. Moreover, COSbased micelles have been designed as carriers of
methotrexate (MTX), a drug used to treat inflammation
and cancer [96]. In this system, MTX was covalently
conjugated with COS to form micelles with particle sizes
of 135–237 nm. In that study, indomethacin-conjugated
COS NPs (IDM-COS NPs) were synthesized for tumortargeted drug delivery [83] using doxorubicin, the
anticancer drug as a cargo. Imaging and in vivo studies
revealed that IDM-COS NPs have great potential to
prolong the circulation time of doxorubicin, enhance
anticancer activity, and improve tumor-targeting ability.
Another COS-based nanomaterial was synthesized to
overcome multidrug resistance in breast cancer cells.
Nanohybrids consisting of silica NPs and copolymers of
COS, polyethyleneimine, and folic acid have been
designed to deliver paclitaxel and short hairpin RNA [97].
COS-based nanomaterials have great potential as protein
delivery vehicles. A previous study reported using COSheparin NPs (COS-hep NPs) to deliver cytokines, which
are small proteins responsible for cell interactions [98].
They used stromal cell-derived factor-1 and vascular
endothelial growth factor as cytokine models and
discovered that COS-hep NPs were significantly stable
under physiological conditions and effectively protected
and delivered cytokines for tissue regeneration. Another
COS-based nanosystem was developed to deliver small
interfering RNA (siRNA) and Vanin-1, which is a
pantethine that catalyzes the hydrolysis of pantetheine

into cysteamine and vitamin B5 [99]. The nanosystem
consists of COS lactate, a P3-peptide, and polyethylene
glycol, and was designed for adipose-targeted delivery.
The results showed that the nanosystem was effective in
attenuating fat mass loss (lipolysis).
COS-based nanomaterials have been developed to
deliver nucleic acids, such as DNA and siRNA, due to
their cationic nature. Redox-responsive COSoctadecylamine NPs have been developed to deliver
DNA specifically used to treat hepatitis B diseases [100].
The NPs were about 250 nm and effectively released
DNA into the cytoplasm (Figure 3). Other studies have
shown that these nanosystems are efficient in delivering
siRNA for treating cancer cells and protecting siRNA
from biodegradation [101].
Recently, COS nanomaterials have been proposed for
novel ocular delivery systems [102] because COS as a
bulk material prevent oxidative stress and inflammation
of the retina [103]. Nanohybrid systems consisting of
nanostructured lipid carriers (NLC) and COS have been
designed to deliver small molecule drugs to the eye [104].
These nanosystems were significantly effective in prolonging precorneal retention and enhancing ocular bioavailability, corneal permeability, and ocular mucoadhesive properties [104, 105]. Recent progress in the application of COS-based nanomaterials for DDS is summarized in Table 1.

Figure 3. Intracellular Trafficking of COS-Octadecylamine NPs. DNA Escaped from the Lysosomes and was Released into
the Cytoplasm, as Indicated in Merge 1 and 2. Lysotracker Blue, FITC, and Cy5 Label Show Lysosomes, COS-based
NPs, and DNA, Respectively. Merge 1 Shows the Merged Images of Red and Blue Channels, while Merge 2 Shows
the Merged Images of the Red and Green Channels. Reproduced from [100] under the Terms of the CC BY-NC-ND
License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Recent Progress in the Application of COS-based Nanomaterials for DDS

Type of
Nanomaterials

Cargo

COS-g-stearic acid

Micelles

Doxorubicin
(DOX)

Redox-responsive release of DOX via
breakable disulfide bond

COS-g-stearic acid

Micelles

DOX

Effective in vitro and in vivo inhibition
effect on tumor and cancer stem cells

COS-indomethacin

Nanoparticles/
conjugates

DOX

Enhanced cytotoxicity of DOX
Prolonged circulation in the blood of mice

Phenylboronic acidPluronic F127-COS

Micelles/
conjugates

DOX

Phenylboronic acid lower IC50 value on
B16 cells
Reduced DOX toxicity to the normal
organs

Nanocomposites

DOX

A pH triggered charge-reversal nano
system
Synergistic effect in tumor inhibition and
lower cardiotoxicity

Nanospheres

Kartogenin and
diclofenac

Thermo-responsive nanosystem with dual
drug release for osteoarthritis treatment
Effective in reducing inflammation and
regenerate cartilage

Nanomaterials

Self-assembly of COS
conjugates and mesoporous
silica nanoparticles
Kartogenin conjugated
COS and dicarboxylated
pluronic F127

Key Findings

Vitamin E-conjugated
COS/Arginine-glycineaspartic acid peptide
(RGD)-conjugated D-alpha
tocopheryl polyethylene
glycol (PEG) 1000
succinate

Mixed micelles

Paclitaxel (PTX)

Sustained PTX release properties and high
cytotoxicity
Effective in killing U87MG tumor in mice

Folic acid-conjugated
COS/magnetic halloysite
nanotubes

Nanocomposites

Camptothecin

Enhanced cellular uptake due to folic acid
and COS

Micelles

Genistein

Dual pH responsive nanomicelles via pH
sensitive benzoic imine and COS
protonation

Biomimetic
nanoplatform

Methotrexate
(MTX)

New nanoformulation-based strategy for
rheumatoid arthritis

Podophyllotoxin
conjugated COS-g-stearic
acid

Micelles

Podophyllotoxin

Enhanced cellular uptake and cytotoxicity
in vitro on glioma cells

Reducible hexadecanol
COS micelles coated with
hyaluronic acid and
polyethylene glycol mixed
with Fe3O4 nanoparticles

Multifunctional
micelles

Gambogic acid

Enhanced cellular uptake and fast drug
release
Redox/pH dual responsive drug release

COS-vanilin imine
Sialic acid-conjugated COS
and biphasic calcium
phosphate

Covalent polyplex between
cationic micelles of COSconjugated polymer and
negatively charged
oligomeric hyaluronic acid
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Multifunctional
nanoparticles

Curcumin

Mitochondrial targeting and chargereversal ability
Effectively localized in mitochondria and
effective tumor reduction in mice
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Table 1. Continue

Nanomaterials
Phycocyanin coated COSdithiopropionic acidcurcumin
Stearic acid-conjugated
COS
COS-valylvaline-stearic
acid

Type of
Nanomaterials

Cargo

Multifunctional
nanoparticles

Curcumin

Micelles

Emodin

Micelles

Key Findings
Redox sensitive via disulfide bond
between curcumin and COS
Enhanced cellular uptake by active
targeting via biotin receptor
Improved antitumor activity of emodin in
vivo

Dexamethasone

Effective in vitro and in vivo ocular
delivery
Comparable to a positive control (Cequa,
which is approved by FDA)
Better release profiles of gallic acid in
neutral pH
Low toxicity of the system on human cell
keratinocytes for concentrations up to 20
g/mL

Pluronic F127 hydrogel
and COS-hyaluronic acid
nanoconjugates

Hydrogel/
Conjugates

Gallic acid

Desalted duck egg whiteCOS conjugate

Conjugates

Calcium

Oleic acid-conjugated
COS-zinc and PLA-PEGPLA copolymer micelles

Nanocomposites

Insulin

Slow controlled release of insulin
Preserving and stabilizing insulin in vivo

Nanoparticles

Vanin-1

Vanin-1, a pantetheinase, regulate
lipolysis and adiposity

P3-peptide COS lactate and
PEG
Spermine-modified COS-gstearic acid
COS-bovine serum
albumin (BSA) conjugate
COS-ss-octadecylamine

Galactosylated COSoctadecylamine

Micelles

DNA

Promoting the escape of DNA release
from endolysosome
Transfection ability of micelles is
comparable with Lipofectamine 2000 and
polyethyleneimine (PEI) 25K

Nanocomplexes

DNA

High in vitro transfection ability and good
cell viability

DNA

Redox-responsive COS-based
nanoparticles for anti-hepatitis B therapy,
with effective transfection ability and
lower cytotoxicity

Nanoparticles

Micelles

DNA

Nanoparticles

siRNA

COS

Nanocomplexes

siRNA

Folic acid-COS and silica
nanohybrids

Nanocomposites

PTX and short
hairpin (shRNA)

Folic acid-modified PEGCOS lactate

Promoting calcium bioavailability and
improving gut health in vivo

Effective in vitro and in vivo gene delivery
for hepatitis B
Glutathione responsive and hepatocytetargeting with no noticeable
hepatotoxicity or systemic toxicity
High efficiency to PDAC (pancreatic
ductal adenocarcinoma) cells
No toxicity in vitro and in vivo was
observed
COS with high DP (more than 50)
produce smaller particle sizes and more
stable complex
Synergistic effect and effective to tackle
multi drug resistance

*No study reported authentication of the cell lines used
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Wound healing. Wound healing is a complex
physiological process involving a series of cellular and
molecular events [120]. The potential of COS in wound
healing is due to their biological activities, such as
antimicrobial, antiinflammatory, immune-enhancing,
cell proliferation, and adhesion-promoting activities
[121], as well as good biocompatibility and costeffectiveness. Therefore, several studies have fabricated
COS-based nanosystems to accelerate wound healing.
One example is a nanofiber composite, consisting of
silver NPs, COS, and poly (vinyl alcohol) [120]. This
system effectively promoted wound healing by
increasing hydroxyproline (hyp) and collagen contents
and activating the TGF1/Smad signaling pathway
(Figure 4). Another nanocomposite was fabricated from
halloysite, a natural nanostructured clay mineral, and
COS [122]. This nanocomposite had a good in vitro
biocompatibility on normal human dermal fibroblast and
enhanced in vitro fibroblast motility, cell proliferation,
and migration. The wound healing ability of the
nanocomposite was significantly better than that of
halloysite or COS separately. A new nanocomposite
consisting of mesoporous glass NPs and COScarboxymethyl starch nanocomplexes was recently
developed to control surgical hemorrhaging [123].

247

Sensors and imaging. The use of nanomaterials for
sensor and imaging applications has gained interest in
recent studies. One class of materials with the capability
for the development of sensors is a water-soluble
responsive polymer. Similarly, COS have attracted
attention in the development of sensor and imaging tools
because of their responsive, biodegradable, and
biocompatible properties. Sensors based on metallic NPs,
such as gold, silver, palladium, and COS, have been
devised to accurately detect H2S and iodide.
Additionally, noninvasive photo imaging for cancer
therapy has been developed [125–127], in which COS
were used as a stabilizer for NPs. Furthermore, targeted
cancer imaging and photothermal therapy have been
performed using fluorescence molecule-conjugated COS
[128], where the COS were conjugated with the ZW8001 near-infrared fluorophore. This system is effective for
targeted tumor imaging and phototermal treatments
(Figure 5). Other approaches using carbon-based
nanomaterials, such as graphene oxide and silica NPs,
were designed to develop sensors for detecting
cholesterol and heparin [91, 129]. A paper-based
colorimetric sensor for detecting glucose and uric acid
has also been developed using COS as the color-forming
reagent [130]. The results showed that COS enhanced the
stability of the colorimetric signals and improved the
clarity of the signal at the detection spot.

Figure 4. Hyp Content (A) and Immunofluorescent Staining of Collagen I and III (B–D) After Treatment with COS-based
Nanofibers. Reproduced from [124] Under the Terms of the Creative Commons Attribution-Non Commercial
License (http://creativecommons.org/licenses/by-nc/3.0/).
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Figure 5. In vivo Tumor-targeting Ability of COS-composite NPs, as Shown in (a). COS-composite NPs Specifically Target the
Tumor, as Indicated by the Fluorescence Signals (White). Tumor is Indicated by the Tu Arrow. The Intensity of the
Fluorescence Signals Decreased Over Time (b). Control is Shown in (c). Biodistribution of COS-composite NPs is
Presented in (d). Reproduced from [128] Under the Terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/).

Conclusions and Perspectives

production method that minimizes the heterogeneity in
the molecular structure is needed.

COS are a promising material to synthesize
polysaccharide-based nanomaterials as they are costeffective and exhibit a wide range of biological activities.
Furthermore, COS have beneficial health effects on the
human body, such as a cholesterol-lowering effect,
antidiabetic, antiinflammatory, and antioxidant activities.
The biological activities of COS depend on the MW and
DD. COS with a lower MW tend to have better biological
activities. Some studies have shown that DP is
significantly important in providing biological and
therapeutic effects.

As most of the raw materials to produce COS are from
crustaceans and seafood, their use could induce
allergenicity and immunogenicity. This is another
concern for the successful commercialization of COSbased nanomaterials for biomedical and pharmaceutical
applications. One way to tackle this problem is by using
noncrustacean-based raw materials, such as fungi. Thus,
the use of fungal COS is encouraged in the future,
although production costs are relatively higher.

Although there has been great progress on COS-based
nanomaterials for biomedical and pharmaceutical
applications in the past decade, some concerns and
obstacles need to be addressed. One concern is the
production of COS as a biomaterial. COS have
heterogeneity in molecular structure as a biopolymer, i.e.,
there are differences in DP, DD, MW, and the type of
polymer chain structure, which affects the reproducibility
and the quality of the synthesized nanomaterials. The
varying molecular structures of COS also hinder the
large-scale production and commercialization of the
synthesized nanomaterials. Therefore, an advanced COS
Makara J. Sci.

In addition, few studies have been conducted on the
safety of COS-based nanomaterials, and clinical trial
research is rare. Thus, it is anticipated that more research
in this area should be a priority in the future. Moreover,
with the advancement of modification technology, COS
derivatives-based nanomaterials could be seen as
potential research topics in the future.
In summary, COS-based nanomaterials had excellent
performance in in vitro and animal studies as a DDS, in
wound healing, and as sensors. However, the
effectiveness and the efficacy of COS-based
nanomaterials for human use remain unknown due to
December 2022  Vol. 26  No. 4
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limited information from clinical trials. Also, for having
reproducible results that can be replicated by other
researchers, validation methods (chemical- and
biological-assays) and the authentication of the cell lines
and microorganisms should be reported in detail.
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